🚀 VC round data is live in beta, check it out!
Oxurion Valuation Multiples
Discover revenue and EBITDA valuation multiples for Oxurion and similar public comparables like Lidds, Altamira Therapeutics, PCI Biotech Holding, Lipigon Pharmaceuticals and more.
Oxurion Overview
About Oxurion
Oxurion NV is a clinical-stage biopharmaceutical company developing next-generation standard-of-care ophthalmic therapies, which are designed to improve and preserve vision in patients with retinal disorders including Geographic Atrophy (GA). The Group’s research and development facilities are located in Belgium. The Company is engaged in the development of drugs to treat blindness diseases.
Founded
2006
HQ
Employees
11
Website
Sectors
Financials (FY)
EV
$13M
Oxurion Financials
Oxurion reported last fiscal year revenue of $3K and EBITDA of $321K.
In the same fiscal year, Oxurion generated ($46K) in gross profit, $321K in EBITDA, and $137K in net income.
Oxurion P&L
In the most recent fiscal year, Oxurion reported revenue of $3K and EBITDA of $321K.
Oxurion expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $3K | XXX | XXX | XXX |
| Gross Profit | — | XXX | ($46K) | XXX | XXX | XXX |
| Gross Margin | — | XXX | (1333%) | XXX | XXX | XXX |
| EBITDA | — | XXX | $321K | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 9267% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 12733% | XXX | XXX | XXX |
| Net Profit | — | XXX | $137K | XXX | XXX | XXX |
| Net Margin | — | XXX | 3967% | XXX | XXX | XXX |
| Net Debt | — | — | $12M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Oxurion Stock Performance
Oxurion has current market cap of $453K, and enterprise value of $13M.
Market Cap Evolution
Oxurion's stock price is $0.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13M | $453K | 0.0% | XXX | XXX | XXX | $0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOxurion Valuation Multiples
Oxurion trades at 3738.9x EV/Revenue multiple, and 40.3x EV/EBITDA.
Oxurion Financial Valuation Multiples
As of March 30, 2026, Oxurion has market cap of $453K and EV of $13M.
Equity research analysts estimate Oxurion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Oxurion has a P/E ratio of 3.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $453K | XXX | $453K | XXX | XXX | XXX |
| EV (current) | $13M | XXX | $13M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 3738.9x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 40.3x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 29.4x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | (280.4x) | XXX | XXX | XXX |
| P/E | — | XXX | 3.3x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (5.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Oxurion Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Oxurion Margins & Growth Rates
Oxurion's revenue in the last fiscal year declined by (99%).
Oxurion's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $-0.0M for the same period.
Oxurion Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (99%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 9267% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (101%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $-0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 333% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 67100% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 45067% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | (14067%) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Oxurion Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Lidds | XXX | XXX | XXX | XXX | XXX | XXX |
| Altamira Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| PCI Biotech Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Lipigon Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| bioXXmed | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oxurion M&A Activity
Oxurion acquired XXX companies to date.
Last acquisition by Oxurion was on XXXXXXXX, XXXXX. Oxurion acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Oxurion
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOxurion Investment Activity
Oxurion invested in XXX companies to date.
Oxurion made its latest investment on XXXXXXXX, XXXXX. Oxurion invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Oxurion
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Oxurion
| When was Oxurion founded? | Oxurion was founded in 2006. |
| Where is Oxurion headquartered? | Oxurion is headquartered in Belgium. |
| How many employees does Oxurion have? | As of today, Oxurion has over 11 employees. |
| Is Oxurion publicly listed? | Yes, Oxurion is a public company listed on Euronext Brussels. |
| What is the stock symbol of Oxurion? | Oxurion trades under OXUR ticker. |
| When did Oxurion go public? | Oxurion went public in 2006. |
| Who are competitors of Oxurion? | Oxurion main competitors are Lidds, Altamira Therapeutics, PCI Biotech Holding, Lipigon Pharmaceuticals. |
| What is the current market cap of Oxurion? | Oxurion's current market cap is $453K. |
| What is the current revenue of Oxurion? | Oxurion's last fiscal year revenue is $3K. |
| What is the current EV/Revenue multiple of Oxurion? | Current revenue multiple of Oxurion is 3738.9x. |
| Is Oxurion profitable? | No, Oxurion is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.